Zhengye Biotechnology Holding Limited - Ordinary Shares (ZYBT)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 3% below Graham Number — thin margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 4.0% — below-average profitability
Zhengye Biotechnology Holding Limited - Ordinary Shares (ZYBT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $36 million . Key value metrics: P/E ratio 23.1, P/B ratio 0.94, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Zhengye Biotechnology Holding Limited - Ordinary Shares — Fundamental Analysis Summary
Zhengye Biotechnology Holding Limited - Ordinary Shares (ZYBT) is trading 3% below its Graham Number of $0.81, offering a thin margin of safety. The stock carries an elevated trailing P/E ratio of 23.1x.
On financial health, ZYBT shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 4.0% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.04.
StockPik's composite Value Score for ZYBT is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ZYBT reports a solid gross margin of 49.0% (sector average: 33.5%) and a modest operating margin of 8.8%.